Vivodyne launches robotic 'human data center' to fix AI drug discovery gap

Biotech startup Vivodyne has launched a "human biological datacenter" across the San Francisco Bay Area and Philadelphia to solve a fundamental data crisis in AI drug discovery. By automating the growth and monitoring of human tissues, the company aims to provide the causal biological data necessary to train AI models that can accurately predict drug efficacy in humans.

At the core of this initiative are modular robotic laboratories known as HIVE. These 12 labs are designed to grow and monitor human tissues at scale, autonomously dosing them and tracking their reactions to various compounds. This approach allows Vivodyne to generate high-fidelity data that bypasses the traditional reliance on animal models. In tests involving 20 chemotherapy drugs, Vivodyne reported high predictive accuracy: 100% concordance for bone marrow, 96% for airway tissue behavior, and 94% for liver cell toxicity.

The failure of animal models

For decades, the pharmaceutical industry has relied on animal testing as a proxy for human response, but the translation is notoriously poor. Industry and regulatory estimates, including data from the FDA and NIH, suggest that between 92% and 95% of drug candidates that appear effective in animal trials ultimately fail to receive regulatory approval for humans.

While AI pioneers like Sam Altman and Demis Hassabis have suggested that artificial intelligence could cure cancer within a decade, actual progress has been slowed by the quality of training data. Most current AI models are trained on static cellular snapshots or animal data, which often fails to mirror the complexity of human biology. As Vivodyne CEO and co-founder Andrei Georgescu puts it, without human testing, AI models are simply going to "cure cancer in mice."

Moving toward predictive engineering

Vivodyne is attempting to shift drug discovery from an experimental "guess-and-check" process to a predictive engineering discipline. The bottleneck for AI in medicine is not a lack of computing power or algorithmic sophistication, but a lack of causal human biological data. By automating the generation of this data through synthetic human tissues, the company seeks to drastically reduce the cost and failure rate of clinical trials.

To support this expansion, Vivodyne raised $40 million in a Series A round reported in mid-2025. The funding is being used to scale the HIVE laboratories and expand the variety of human tissues the system can monitor.

What remains to be seen

While the initial predictive accuracy for chemotherapy drugs is promising, the broader challenge remains whether this synthetic data can consistently replace the complex systemic interactions of a living human body. The industry will be watching to see if Vivodyne's high-fidelity data can lead to a measurable increase in the success rate of human clinical trials, moving the needle on the 95% failure rate that currently plagues the sector.